SCHEMBL22320365

SCHEMBL22320365

CC1(C(N)=O)CCN(c2nccc(CO)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.42
▸ AOC3 Q16853 2/20 0.41
▸ EIF2AK4 Q9P2K8 1/20 0.40
▸ PTPN11 Q06124 6/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SORD Q00796 2/20 0.36
▸ PANK3 Q9H999 1/20 0.36
▸ NR1H2 P55055 1/20 0.36
▸ CYP3A4 P08684 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ CYP2C19 P33261 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20745663 0.84 SORD (0.41) AOC3PTPN11MEN1KMT2ASORD
SCHEMBL22320681 0.80 ACHE (0.38) AOC3PTPN11MEN1KMT2ASORD
SCHEMBL20746494 0.78 TRPV3 (0.42) AOC3SORDPANK3NR1H2
SCHEMBL20745046 0.76 AOC3 (0.37) AOC3PTPN11MEN1KMT2ASORD
SCHEMBL20746025 0.76 DYRK1A (0.41) SORDCYP3A4CYP2C19CYP1A2CYP2D6
SCHEMBL22262720 0.76 ACHE (0.39) SORD
SCHEMBL16815333 0.75 ACHE (0.50) SORD
SCHEMBL28562329 0.75 RET (0.42) CYP3A4
SCHEMBL28059125 0.74 ACHE (0.46) MEN1KMT2ASORDCYP3A4CYP2C19
SCHEMBL16815392 0.73 PIK3CA (0.51) SORDMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112739343-A Macrocyclic MCL-1 inhibitors and methods of use 艾伯维公司 2021-04-30 — — CN disclosed
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2020-08-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 EGFR 1079/4885AOC3 3230/4885EIF2AK4 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback